- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01239108
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
January 13, 2020 updated by: Astex Pharmaceuticals, Inc.
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.
Study Overview
Detailed Description
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women with a confirmed diagnosis of leukemia unresponsive to curative therapy
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Total bilirubin ≤ 1.5 X upper limit of normal (ULN); aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 3 X ULN; serum creatinine ≤ 2 X ULN
- Normal cardiac function with left ventricular ejection fraction ≥ 50% at screening
- No clinically significant abnormalities on screening electrocardiogram (ie, QTc interval must be < 470 msec for women and < 450 msec for men and no history of torsades de pointes)
- No reproductive potential or willing to use 2 methods of contraception during the study and for 30 days after the last dose
- Able to understand the purpose and risks of the study and provide informed consent and authorization to use protected health information
Exclusion Criteria:
- A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral SGI-1776, or put the study outcomes at undue risk
- Significant cardiovascular disease
- Malabsorption syndrome
- Symptomatic central nervous system metastases or lesions for which treatment is required
- Received prior radiation therapy within 4 weeks of first dose
- Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation
- Treatment with any investigational drug within 3 weeks of the first dose
- Use of systemic corticosteroids (other than for premedications or intermittent doses such as those used for allergic reactions and control of asthma) or myelosuppressive chemotherapy within 2 weeks of the first dose treatment with nitrosoureas or mitomycin C within 3 weeks of the first dose of SGI 1776
- Uncontrolled active systemic infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The MTD as determined by the incidence of DLTs in the first 4 weeks of each dosing cohort
Time Frame: July 2011
|
July 2011
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Frequency, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) •
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Anticipated)
April 1, 2012
Study Completion (Anticipated)
April 1, 2012
Study Registration Dates
First Submitted
November 5, 2010
First Submitted That Met QC Criteria
November 9, 2010
First Posted (Estimate)
November 11, 2010
Study Record Updates
Last Update Posted (Actual)
January 18, 2020
Last Update Submitted That Met QC Criteria
January 13, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SGI-1776-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Leukemias
-
Case Comprehensive Cancer CenterFlorida International University; Community Foundation of BrowardRecruitingRelapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Nantes University HospitalWithdrawnCD22+ Relapsed/Refractory B-ALLFrance
-
Stanford UniversityAmgen; Pediatric Oncology Experimental Therapeutics Investigators' ConsortiumCompletedRefractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed LeukemiaUnited States, Canada
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory B-Cell MalignanciesChina, Australia
-
Minghui Pharmaceutical (Shanghai) LTDRecruitingRelapsed/Refractory B-cell MalignanciesChina
-
Gilead SciencesCompletedRelapsed/Refractory B-cell MalignanciesFrance, United Kingdom
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Xinxiang medical universityRecruiting
Clinical Trials on SGI-1776
-
Astex Pharmaceuticals, Inc.TerminatedProstate Cancer | Non-Hodgkins LymphomaUnited Kingdom, United States
-
ShireCompletedMigraine HeadacheUnited States
-
National University, SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingMental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Cognitive Impairment | Dementia | Alzheimer Disease | Cognition Disorder | Vascular Cognitive ImpairmentSingapore
-
Astex Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Myeloid Dysplastic SyndromeUnited States, Taiwan, Korea, Republic of, Canada, Spain, Japan, Italy, Austria, Denmark
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Zhejiang UniversityRecruitingBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Cognitive Impairment | Alzheimer Disease | Mental Disorder | Cognition Disorder | Vascular Cognitive Impairment | DementChina
-
Weill Medical College of Cornell UniversityAstex Pharmaceuticals, Inc.CompletedMyeloproliferative NeoplasmsUnited States
-
Astex Pharmaceuticals, Inc.CompletedHepatocellular CarcinomaUnited States, United Kingdom, Canada
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Groupe Francophone des MyelodysplasiesUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromesFrance